Avid Bioservices Inc (CDMO) Return on Equity ROE from the second quarter 2025 to second quarter 2024 and annually, average high and low, overall ranking from Oct 31 2024 to Oct 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Avid Bioservices Inc   (NASDAQ: CDMO)

Avid Bioservices Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Avid Bioservices Inc in the second quarter 2025?
Avid Bioservices Inc recorded a cumulative net loss of $-152 million during 12 months ending in the second quarter 2025, resulting in a negative return on equity (ROE) of -176.54%.

Within the Major Pharmaceutical Preparations industry 295 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2025 from 3375 to 3574.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Oct 31 2024)
II. Quarter		 (Jul 31 2024)
I. Quarter		 (Apr 30 2024)
IV. Quarter		 (Jan 31 2024)
III. Quarter		 (Oct 31 2023)
II. Quarter
Y / Y Equity Change -75.56 % -69.18 % -67.81 % -2.82 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -152 -144 -141 -18 -12
Return On Equity (TTM) -176.54 % -119.38 % -91.6 % -9.67 % -6.52 %
CDMO's Total Ranking # 3574 # 3375 # 2767 # 2338 # 2455
Equity (TTM) in Millions 45 59 61 180 183
Seq. Equity Change -23.58 % -3.7 % -66.2 % -1.73 % -3.64 %
Seq. Net Income Change - - - - -

Back to CDMO Management Effectiveness >> CDMO's 5 Years Annual ROE >> Compare CDMO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 296
Sector # 663
Overall # 3574

Return On Equity Statistics
High Average Low
156.25 %
-31.69 %
-176.54 %
(Apr 30 2022)   (Oct 31 2024)





CDMO Annual Return On Equity (Apr 30 2024)
2024		 (Apr 30 2023)
2023		 (Apr 30 2022)
2022		 (Apr 30 2021)
2021		 (Apr 30 2020)
2020
Total Equity in Millions 61 189 175 78 42
Y / Y Equity Change -67.81 % 8.39 % 124.51 % 85.55 % -21.05 %
Net Income in Millions -141 0 128 11 -10
Y / Y Net Income Change - -99.8 % 1038.71 % - -
Return On Equity -231.16 % 0.14 % 73.15 % 14.42 % -24.98 %

Back to CDMO Management Effectiveness >> CDMO's 5 Years Annual ROE >> Compare CDMO ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CDMO's' Return on Equity at Yahoo Finance
CDMO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CDMO's Competitors
Subscribers only: Roe for Avid Bioservices Inc 's Suppliers
Subscribers only: Return On Equity for CDMO's Customers




Companies with similar Return On Equity at Oct 31 2024, within Healthcare Sector ROE

Date modified: 2026-09-08T15:11:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.